AstraZeneca may not stay in the vaccine business in the long run, its CEO told Reuters on Tuesday, showing how quickly fortunes have changed for the drugmaker that produced one of the first COVID-19 shots but has since lost out to rivals.
The U.S. Centers for Disease Control and Prevention (CDC) on Monday signed off on the use of Novavax Inc.’s COVID-19 vaccine for adolescents aged 12 through 17.
The World Health Organization (WHO) on Thursday recommended the use of French drugmaker Valneva’s COVID-19 vaccine.
Novavax Inc. said on Monday it had filed for U.S. authorization for use of its COVID-19 vaccine as a booster dose in people who had either received its shots or a different vaccine.
The biopharma industry’s response to the global pandemic has propelled some COVID-19 vaccines into the leading ranks of the world’s best-selling products, with Pfizer/BioNTech’s Comirnaty surpassing AbbVie’s Humira for the No. 1 spot.
Emergent BioSolutions Inc. said on Friday it had received a warning letter from the U.S. Food and Drug Administration, citing certain deficiencies at the contract drugmaker’s manufacturing facility in Baltimore, Maryland.
People at high risk of severe disease who have yet to get a second COVID-19 booster should not wait for next-generation, Omicron-targeted vaccines expected in the fall, five vaccine experts told Reuters.
The BA.5 subvariant of Omicron was estimated to make up 81.9% of the circulating coronavirus variants in the United States for the week ended July 23, the U.S. Centers for Disease Control and Prevention (CDC) said on Tuesday.
Johnson & Johnson on Tuesday reported quarterly results that beat analysts’ estimates on strong demand for cancer drug Darzalex and its COVID-19 vaccine, even as the company cut its full-year adjusted profit forecast due to a stronger dollar.
The European Medicines Agency on Monday started reviewing a low-dose version of BioNTech and Pfizer’s COVID-19 vaccine for use in children between the age of six months and four years.